The results of a recent systematic review evaluating the benefits and harms of statins compared with placebo in COPD patients showed that statin use can reduce CRP and IL-6 levels, but there were no significant gains in COPD mortality, exacerbation frequency, or lung function (97). This evidence concerns the gene CRP and chronic obstructive pulmonary disease.